Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter
Professionals >> Visit The Body PROThe Body en Espanol
Home Page for TheBody.com, the Complete HIV/AIDS Resource What's New About HIV Ask the Experts About HIV HIV/AIDS Blogs Connect With Others About HIV Just Diagnosed With HIV HIV Treatment HIV Prevention Living With HIV Personal Stories of People With HIV
Take Tell Us What YOU Think! Take The Body's Visitor Survey!
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

Tenofovir Expanded Access

From AIDS Community Research Initiative of America

Spring 2001

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Tenofovir DF, Gilead Sciences' experimental nucleotide analogue, is now available through a small expanded access program.

To qualify, you must:

  • Be at least 18 years old;

  • Have a viral load greater than or equal to 10,000 copies and a CD4 count below 100, or

    Advertisement
    a CD4 count below 200 and an opportunistic infection within the past three months;

  • Have had treatment failure with or intolerance to at least two protease inhibitors (PIs) or one PI and one NNRTI; and

  • Be unable to put together a useful drug combination with available antivirals.

To register in the program, your doctor should call 800-445-3235.

The dose is 300mg taken once a day. Tenofovir DF is expected to be considered for FDA approval this summer. Hopefully, the program criteria will be expanded before then.


A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF
This article was provided by AIDS Community Research Initiative of America. It is a part of the publication CRIA Update.
 
See Also
More on HIV Medications
More News on Tenofovir (Viread)

 

Advertisement